News
CADL
8.67
+2.00%
0.17
Weekly Report: what happened at CADL last week (0601-0605)?
Weekly Report · 1d ago
Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target
TipRanks · 06/02 16:45
Candel Publishes Phase 3 Results For Aglatimagene In Treating Prostate Cancer, Notes Improved DFS
NASDAQ · 06/02 15:26
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
TipRanks · 06/02 14:27
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer
Benzinga · 06/02 12:19
Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer
PUBT · 06/02 12:09
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Barchart · 06/02 07:05
Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each
PUBT · 06/01 20:08
CANDEL THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:05
Weekly Report: what happened at CADL last week (0525-0529)?
Weekly Report · 06/01 09:41
Bank of America Securities Remains a Hold on Candel Therapeutics (CADL)
TipRanks · 06/01 01:19
Weekly Report: what happened at CADL last week (0518-0522)?
Weekly Report · 05/25 09:43
Candel Therapeutics price target raised to $9 from $7 at BofA
TipRanks · 05/18 19:30
Candel Reports Positive Phase 3 Follow-Up Data For Aglatimagene In Prostate Cancer
NASDAQ · 05/18 10:55
Weekly Report: what happened at CADL last week (0511-0515)?
Weekly Report · 05/18 09:43
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Benzinga · 05/16 18:47
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
TipRanks · 05/15 22:08
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting
Benzinga · 05/15 20:07
Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up
PUBT · 05/15 20:07
CANDEL THERAPEUTICS REPORTS EXTENDED CLINICAL BENEFIT OVER MULTIPLE CLINICAL ENDPOINTS IN PATIENTS FROM PHASE 3 TRIAL OF AGLATIMAGENE BESADENOVEC (CAN-2409) IN LOCALIZED PROSTATE CANCER UNDER PROLONGED FOLLOW-UP AT AUA 2026 ANNUAL MEETING
Reuters · 05/15 20:05
More
Webull provides a variety of real-time CADL stock news. You can receive the latest news about Candel Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.